SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Hein A) "

Sökning: WFRF:(Hein A)

  • Resultat 11-20 av 219
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
11.
  • Kobel, M., et al. (författare)
  • p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
  • 2023
  • Ingår i: Journal of Pathology Clinical Research. - : Wiley. - 2056-4538. ; 9:3, s. 208-222
  • Tidskriftsartikel (refereegranskat)abstract
    • Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi-institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, and cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency of abnormal p53 expression was 93.4% (4,630/4,957) in HGSC compared to 11.9% (116/973) in EC and 11.5% (86/748) in CCC. In HGSC, there were no differences in overall survival across the abnormal p53 expression patterns. However, in EC and CCC, abnormal p53 expression was associated with an increased risk of death for women diagnosed with EC in multivariate analysis compared to normal p53 as the reference (hazard ratio [HR] = 2.18, 95% confidence interval [CI] 1.36-3.47, p = 0.0011) and with CCC (HR = 1.57, 95% CI 1.11-2.22, p = 0.012). Abnormal p53 was also associated with shorter overall survival in The International Federation of Gynecology and Obstetrics stage I/II EC and CCC. Our study provides further evidence that functional groups of TP53 mutations assessed by abnormal surrogate p53 IHC patterns are not associated with survival in HGSC. In contrast, we validate that abnormal p53 IHC is a strong independent prognostic marker for EC and demonstrate for the first time an independent prognostic association of abnormal p53 IHC with overall survival in patients with CCC.
  •  
12.
  • Kang, E. Y., et al. (författare)
  • MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma
  • 2022
  • Ingår i: Virchows Archiv. - : Springer Science and Business Media LLC. - 0945-6317 .- 1432-2307. ; 480
  • Tidskriftsartikel (refereegranskat)abstract
    • Tubo-ovarian high-grade serous carcinomas (HGSC) are highly proliferative neoplasms that generally respond well to platinum/taxane chemotherapy. We recently identified minichromosome maintenance complex component 3 (MCM3), which is involved in the initiation of DNA replication and proliferation, as a favorable prognostic marker in HGSC. Our objective was to further validate whether MCM3 mRNA expression and possibly MCM3 protein levels are associated with survival in patients with HGSC. MCM3 mRNA expression was measured using NanoString expression profiling on formalin-fixed and paraffin-embedded tissue (N = 2355 HGSC) and MCM3 protein expression was assessed by immunohistochemistry (N = 522 HGSC) and compared with Ki-67. Kaplan-Meier curves and the Cox proportional hazards model were used to estimate associations with survival. Among chemotherapy-naive HGSC, higher MCM3 mRNA expression (one standard deviation increase in the score) was associated with longer overall survival (HR = 0.87, 95% CI 0.81-0.92, p < 0.0001, N = 1840) in multivariable analysis. MCM3 mRNA expression was highest in the HGSC C5.PRO molecular subtype, although no interaction was observed between MCM3, survival and molecular subtypes. MCM3 and Ki-67 protein levels were significantly lower after exposure to neoadjuvant chemotherapy compared to chemotherapy-naive tumors: 37.0% versus 46.4% and 22.9% versus 34.2%, respectively. Among chemotherapy-naive HGSC, high MCM3 protein levels were also associated with significantly longer disease-specific survival (HR = 0.52, 95% CI 0.36-0.74, p = 0.0003, N = 392) compared to cases with low MCM3 protein levels in multivariable analysis. MCM3 immunohistochemistry is a promising surrogate marker of proliferation in HGSC.
  •  
13.
  •  
14.
  •  
15.
  •  
16.
  •  
17.
  •  
18.
  •  
19.
  •  
20.
  • Hollestelle, Antoinette, et al. (författare)
  • No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
  • 2016
  • Ingår i: Gynecologic Oncology. - : Elsevier BV. - 0090-8258 .- 1095-6859. ; 141:2, s. 386-401
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3′ UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome associated with rs61764370. Methods Centralized genotyping and analysis were performed for 140,012 women enrolled in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and the Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7904 BRCA2 mutation carriers). Results We found no association with risk of ovarian cancer (OR = 0.99, 95% CI 0.94-1.04, p = 0.74) or breast cancer (OR = 0.98, 95% CI 0.94-1.01, p = 0.19) and results were consistent among mutation carriers (BRCA1, ovarian cancer HR = 1.09, 95% CI 0.97-1.23, p = 0.14, breast cancer HR = 1.04, 95% CI 0.97-1.12, p = 0.27; BRCA2, ovarian cancer HR = 0.89, 95% CI 0.71-1.13, p = 0.34, breast cancer HR = 1.06, 95% CI 0.94-1.19, p = 0.35). Null results were also obtained for associations with overall survival following ovarian cancer (HR = 0.94, 95% CI 0.83-1.07, p = 0.38), breast cancer (HR = 0.96, 95% CI 0.87-1.06, p = 0.38), and all other previously-reported associations. Conclusions rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical utility related to the prediction or management of these cancers.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 11-20 av 219
Typ av publikation
tidskriftsartikel (198)
konferensbidrag (11)
forskningsöversikt (8)
annan publikation (2)
Typ av innehåll
refereegranskat (210)
övrigt vetenskapligt/konstnärligt (9)
Författare/redaktör
Chang-Claude, J (52)
Easton, DF (50)
Hall, P (49)
Fasching, PA (48)
Beckmann, MW (48)
Lambrechts, D (47)
visa fler...
Czene, K (46)
Giles, GG (45)
Dunning, AM (43)
Ekici, AB (43)
Couch, FJ (43)
Hopper, JL (40)
Garcia-Closas, M (40)
Southey, MC (39)
Cox, A (39)
Pharoah, PDP (39)
Nevanlinna, H (38)
Dork, T (37)
Anton-Culver, H (35)
Milne, RL (35)
Brauch, H (35)
Burwinkel, B (35)
Chenevix-Trench, G (35)
Peto, J (34)
Lissowska, J (34)
Brenner, H (33)
Lindblom, A (33)
Dennis, J (32)
Jakubowska, A (32)
Benitez, J. (31)
Andrulis, IL (31)
Mannermaa, A (31)
Chanock, SJ (31)
Blomqvist, C (30)
Bolla, MK (30)
Margolin, S (30)
Tomlinson, I (30)
Shah, M (30)
Lubinski, J (30)
Hamann, U (29)
Schmidt, MK (29)
Bojesen, SE (28)
Kosma, VM (28)
Michailidou, K (27)
Radice, P (27)
Flesch-Janys, D (27)
Haiman, CA (27)
Tollenaar, RAEM (27)
Aittomaki, K (27)
Flyger, H (27)
visa färre...
Lärosäte
Karolinska Institutet (106)
Uppsala universitet (61)
Lunds universitet (27)
Göteborgs universitet (22)
Umeå universitet (11)
Kungliga Tekniska Högskolan (11)
visa fler...
Linköpings universitet (10)
Stockholms universitet (5)
Luleå tekniska universitet (4)
Gymnastik- och idrottshögskolan (4)
Handelshögskolan i Stockholm (2)
Chalmers tekniska högskola (2)
Örebro universitet (1)
Karlstads universitet (1)
visa färre...
Språk
Engelska (216)
Ryska (1)
Italienska (1)
Polska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (96)
Naturvetenskap (23)
Teknik (7)
Samhällsvetenskap (4)
Lantbruksvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy